Recurrent Gastric Cancer Completed Phase 2 Trials for Bevacizumab (DB00112)

Also known as: Gastric cancer recurrent / Stomach cancer recurrent / Stomach carcinoma recurrent / Gastric carcinoma recurrent

IndicationStatusPhase
DBCOND0028800 (Recurrent Gastric Cancer)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00084604Irinotecan, Cisplatin, and Bevacizumab in Treating Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaTreatment